Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 17, 2014
Pharmacy Choice - News - Generic Drugs - April 17, 2014

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 61     Next >>     Go To Page:

4/17/14 - Actavis Announces Agreement Related to Generess FE Patent Challenge Litigation [Global Data Point]
Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending Abbreviated New Drug Application beginning on April 1, 2015.&# x0D;. Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on October 1, 2015. Actavis remains i
4/17/14 - Akorn Completes Acquisition of Hi-Tech Pharmacal
Akorn, Inc., a niche pharmaceutical company, announced today that it has completed its previously announced acquisition of Hi-Tech Pharmacal Co., Inc. for $640 million in cash. The combination of Akorn and Hi-Tech will transform the Company into a larger, more diversified generic player. We are excited to announce that we have completed the acqu
4/17/14 - Biosimilars Market by Product & Application - Global Forecast to 2018
Dublin- Research and Markets has announced the addition of the "Biosimilars Market by Product& Application- Global Forecast to 2018" report to their offering. The global market is segmented on the basis of products, applications, and services. The global market will be worth $2.0 billion by 2018, growing at a CAGR of 20.1% during the forecast perio
4/17/14 - JCM Updates on Azithromycin API Export
Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics, and active pharmaceutical ingredients, updated regarding the recent progress of the Jiangchuan Macrolide Facility. JCM has developed a new line of...
4/17/14 - Teva recalls anti-depressant - report [Globes, Tel Aviv, Israel :: ]
Teva began marketing its generic version of the drug in the fourth quarter of 2012.. Teva produces generic Cymbalta at its plant in Jerusalem. "The safety and efficacy of our medicines is one of Teva's top priorities.
4/17/14 - Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received Tenative FDA Approval for All Strengths; May Start Generic Versions in December
Teva Pharmaceutical Industries Ltd. announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer related to Teva's generic version of Celebrex 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier
4/17/14 - Teva Settles Patent Litigation with Pfizer on Celebrex
Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the U.S. Food and Drug Administration for all strengths and believes that it is first-to-file on at least the 100, 200 and 400 mg capsules. Headquartered in Israel, Teva is the
4/17/14 - ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool
By a News Reporter-Staff News Editor at Politics& Government Week ViiV Healthcare announced new collaborations with the goal of increasing access to its HIV medicine, dolutegravir, just two months after its approval by the European Medicines Agency and eight months after approval by the US Food and Drug Administration. Through an agreement with t
4/16/14 - Actavis Acquires Silom Medical Company
By a News Reporter-Staff News Editor at Biotech Week Actavis plc, a leading global specialty pharmaceutical company announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash. "Silom Medical's diverse produ
4/16/14 - AMRI Finalizes Acquisition of Cedarburg Pharmaceuticals [Professional Services Close - Up]
AMRI announced that it has completed the previously announced acquisition of Cedarburg Pharmaceuticals, Inc.. According to a release, Cedarburg, whose capabilities both augment and complement those of AMRI, is a contract developer and manufacturer of technically complex active pharmaceutical ingredients for both generic and branded customers.
4/16/14 - Boston Scientific Reports FDA Approval for Heart Failure Devices; Teva Unveils Generic Lunesta Tablets in US
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 15, 2014.{ nfg} Boston Scientific Corporation has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. These newly approved devices continue the Boston Scientific history of
4/16/14 - BRIEF: Teva launches generic insomnia treatment in US [Globes, Tel Aviv, Israel :: ]
April 16 Teva Pharmaceutical Industries Ltd. has launched generic Lunesta, for the treatment of insomnia, in the US. Brand Lunesta, marketed by Sunovion Pharmaceuticals Inc., had $852 million in US sales in 2013, according to IMS. Glenmark Generics Ltd. and Mylan Inc. also obtained marketing approval for generic Lunesta.
4/16/14 - Cadila, Depomed settle case on gapapentin [India Business] [Times of India]
MUMBAI: Ahmedabad-based Cadila Healthcare and Zydus Pharmaceuticals Inc, a generic pharma company in the US, announced that they have entered into a settlement agreement with Depomed, Inc to settle their ongoing patent infringement litigation related to Gralise 300 mg and 600 mg tablets. The settlement permits Cadila and Zydus to begin selling gene
4/16/14 - Contract Pharmaceutical Research Services in the US Industry Market Research Report Now Available from IBISWorld
The industry provides a breadth of research and development services to manufacturers in the pharmaceutical industries. In the past five years, brand-name drug producers have faced increasing threats from generic brands due to patent expirations. According to IBISWorld Industry Analyst Darryle Ullama, "In the five years to 2014, industry revenue is
4/16/14 - Dr. Reddy's Announces the Launch of Eszopiclone Tablets C-IV
Dr. Reddy s Laboratories announced today that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA tablets C-IV in the US market on April 15, 2014, following the approval by the United States Food& Drug Administration. The LUNESTA tablets C-IV brand and generic combined had U.S. sales
4/16/14 - Findings on Biologics Reported by E. Choy et al
According to news reporting from New York City, New York, by NewsRx journalists, research stated, "Biologics are important treatments for a number of cancers. For more information on this research see: Biosimilar Safety Considerations in Clinical Practice. Seminars in Oncology, 2014; 41: S3-S14. Seminars in Oncology can be contacted at: W B Saunder
4/16/14 - Impax Launches Authorized Generic RENVELA
Impax Laboratories, Inc. today announced that it is commencing shipment of authorized generic RENVELA, through Global Pharmaceuticals, Impax's generics division. Impax continues to pursue approval of its pending Abbreviated New Drug Application for generic RENVELA with the U.S. Food and Drug Administration. Impax markets its generic products throug
4/16/14 - Mylan Launches First Generic ORTHO EVRA Patch
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE?, the generic version of Janssen Pharmaceuticals Inc.' s ORTHO EVRA *. ORTHO EVRA had U.S. sales of approximately $152.9 million for the 12 months ending Dec. 30, 2013, according to IMS Health. Currently, Mylan has 300 ANDAs pending FDA appr
4/16/14 - Noven Announces Settlement of Lidoderm Patent Litigation
MIAMI& NEW YORK Noven Pharmaceuticals, Inc. today announced that it has entered into an agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related to Noven s lidocaine topical patch 5% product. The agreement allows Noven to launch its generic Lidoderm
4/16/14 - NUVA Announces Licensing Agreements for 48 Generic Drugs for Canadian Markets
is pleased to announce that it has signed Cross Referencing Agreements for prescription generic products for Canadian markets. NUVA is in the process of securing a Drug Establishment License from Health Canada. Upon receipt of the DEL, NUVA will start filing for regulatory approval of these products with Health Canada.
4/16/14 - Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines
Dublin- Research and Markets has announced the addition of the "Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines" report to their offering. This research was designed to provide pharmaceutical sales, marketing, and brand management with data to better understand how US patients will make decisions regarding their.
4/16/14 - Research and Markets: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines
Research and Markets has announced the addition of the "Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines" report to their offering. This research was designed to provide pharmaceutical sales, marketing, and brand management with data to better understand how US patients will make decisions regarding their purchase
4/16/14 - Research and Markets: World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others
Research and Markets has announced the addition of the "The World Market for Biosimilars, 4th Edition" report to their offering. The World Market for Biosimilars, predicts a market of nearly $5 billion dollars in the next five years. Absence of such regulation and biosimilars approval process in other countries, in particular in the United States,
4/16/14 - Statement by Ralph G. Neas, President and CEO, GPhA, Regarding IMS Findings on the Use of Medicines in 2013
Generic Pharmaceutical Association issued the following statement by Ralph G. Neas, President and CEO:. "The Generic Pharmaceutical Association welcomes this year's IMS Institute for Healthcare Informatics report showing the critical role of generic medicines in saving billions of dollars for the health system and the economy. Indeed, an IMS healt
4/16/14 - Switzerland : Roche with good start in 2014 [TendersInfo (India)]
Sales of Xeloda, a chemotherapy drug, were lower as the product is now off patent and faces generic competition in the United States and Europe. In the Diagnostics Division, strong sales growth was driven mainly by Professional Diagnostics with demand for immunoassays in clinical laboratories. Acquisition of IQuum strengthens Molecular Diagnostics.
Articles(s): 1 - 25 of 61     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool
An Overview of Complementary and Alternative Medicine
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415